A New Integrative Modeling Approach for Generating Counterfactual Projections of Colorectal Cancer Incidence Rates in the Absence of Organized Screening in Australia.
BackgroundThe Australian National Bowel Cancer Screening Program (NBCSP), which provides 2-yearly screening to people aged 50 to 74 y, had a phased rollout from 2006 and was fully implemented in 2020.
APA
Luo Q, Lew JB, et al. (2026). A New Integrative Modeling Approach for Generating Counterfactual Projections of Colorectal Cancer Incidence Rates in the Absence of Organized Screening in Australia.. Medical decision making : an international journal of the Society for Medical Decision Making, 46(2), 189-201. https://doi.org/10.1177/0272989X251393257
MLA
Luo Q, et al.. "A New Integrative Modeling Approach for Generating Counterfactual Projections of Colorectal Cancer Incidence Rates in the Absence of Organized Screening in Australia.." Medical decision making : an international journal of the Society for Medical Decision Making, vol. 46, no. 2, 2026, pp. 189-201.
PMID
41263263
Abstract
BackgroundThe Australian National Bowel Cancer Screening Program (NBCSP), which provides 2-yearly screening to people aged 50 to 74 y, had a phased rollout from 2006 and was fully implemented in 2020. To measure the effectiveness of the NBCSP accounting for age-specific trends, we aimed to develop a novel integrative method to project colorectal cancer (CRC) incidence rates from 2006 to 2045 in the absence of the NBCSP (referred to as "no-NBCSP projections") while addressing the challenge of complex age-specific trends in CRC incidence.MethodsWe constructed a new dataset by replacing the observed data for NBCSP-eligible individuals aged 50 to 74 y with intermediate projections based on pre-NBCSP data from 1982 to 2005. We compared the no-NBCSP CRC incidence projected using a standard age-period-cohort (APC) model, age-stratified APC models, and the integrative modeling approach.ResultsThe integrative modeling approach captured complex age-specific trends better than the standard and age-stratified APC models did. Without the NBCSP, the overall CRC incidence rates would be expected to decline from 2005 to 2025, followed by increases from 2026 to 2045. The incidence rates for those aged <50 y would be projected to continue increasing to 2045, and an increase in incidence rates for older age groups would be projected to occur from 2020 for ages 50 to 54 y, from 2030 for ages 65 to 74 y, and from 2035 for ages 75 y and older.ConclusionsThese no-NBCSP projections provide a counterfactual benchmark against which to measure the impact of the NBCSP on CRC incidence in Australia, and they have been used as new calibration targets for a simulation model of CRC and screening in Australia. The methods developed here could be used to generate comparators to assess the impact of other public health interventions.HighlightsWe constructed counterfactual projections of colorectal cancer (CRC) incidence rates in the absence of the National Bowel Cancer Screening Program (no-NBCSP projections).To do this, we developed a new integrative modeling approach to capture complex age-specific colorectal cancer incidence trends.These no-NBCSP projections provide a counterfactual benchmark against which to measure the impact of the NBCSP on CRC incidence in Australia.These projections stress the need for ongoing assessment of the starting age for the NBCSP, to tackle the increasing incidence for people younger than 50 y.
MeSH Terms
Humans; Colorectal Neoplasms; Middle Aged; Australia; Aged; Incidence; Male; Female; Early Detection of Cancer; Mass Screening; Forecasting; Age Factors
같은 제1저자의 인용 많은 논문 (5)
- Contrast-enhanced CT-based radiomics for predicting visceral pleural invasion in early-stage non-small cell lung cancer.
- Age-Based Left-Digit Bias in the Treatment of Pancreatic Adenocarcinoma.
- Associations of serum lipid traits with DLBCL: a prospective cohort study from the UK Biobank.
- NCAPD2 Modulates MHC-I Antigen Presentation via the PI3K/AKT Axis to Drive Metastatic Progression in Gastric Cancer.
- Development and external validation of interpretable machine learning models for personalized multiple treatment recommendations in non-small cell lung cancer.